Vilin Bio Med (NSE:VILINBIO) EBIT : ₹14.21 Mil (TTM As of Sep. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Vilin Bio Med EBIT?

Vilin Bio Med's earnings before interest and taxes (EBIT) for the six months ended in Sep. 2023 was ₹14.21 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was ₹14.21 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Vilin Bio Med's annualized ROC % for the quarter that ended in Sep. 2023 was 8.20%. Vilin Bio Med's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 15.49%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Vilin Bio Med's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 5.57%.

Vilin Bio Med EBIT Historical Data

The historical data trend for Vilin Bio Med's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vilin Bio Med EBIT Chart

Vilin Bio Med Annual Data

Trend

Mar20

Mar21

Mar22

EBIT

5.74

5.76

5.40

Vilin Bio Med Semi-Annual Data
	Mar20	Mar21	Mar22	Sep22	Sep23
EBIT	-	-	-	10.21	14.21

Competitive Comparison of Vilin Bio Med's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Vilin Bio Med's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vilin Bio Med's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vilin Bio Med's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Vilin Bio Med's EV-to-EBIT falls into.

Vilin Bio Med EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹14.21 Mil.

Vilin Bio Med (NSE:VILINBIO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Vilin Bio Med's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

	ROC % (Q: Sep. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2022 )	+	Invested Capital (Q: Sep. 2023 ))	/ count )
=	26.254 * ( 1 - 26.27% )	/	( (0	+	235.949)	/ 1 )
=	19.3570742	/	235.949
=	8.20 %

where

	Invested Capital		(Q: Sep. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0	-	0	-	( 0	-	max(0, 0	-	0	+	0	))
=	0

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	309.444	-	8.171	-	( 65.324	-	max(0, 71.722	-	266.248	+	65.324	))
=	235.949

Note: The Operating Income data used here is two times the semi-annual (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Vilin Bio Med's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2022		Q: Sep. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	28.416	/	( ( (0 + max(0, 0))	+	(14.35 + max(169.152, 0)) )	/	1 )
=	28.416	/	( ( 0	+	183.502 )	/	1 )
=	28.416	/	183.502
=	15.49 %

where Working Capital is:

	Working Capital		(Q: Sep. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0	+	0	+	0)
=	0

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(112.722	+	24.375	+	51.06)	-	(8.171	+	0	+	10.834)
=	169.152

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Vilin Bio Med's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2023 )
	=	14.208	/	254.968
	=	5.57 %

Vilin Bio Med EBIT Related Terms

Thank you for viewing the detailed overview of Vilin Bio Med's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Vilin Bio Med (NSE:VILINBIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vilin Bio Med Ltd (NSE:VILINBIO) » Definitions » EBIT

Traded in Other Exchanges

N/A

Address

Opposite Sub Registrar’s Office, Survey No.115/GF/J, Hanumanji Colony, Bowempally, Secunderabad, TG, IND, 500009

Website

http://www.vilinbiomed.co.in

Vilin Bio Med Ltd is engaged in the domestic business of manufacturing Pharmaceuticals products. It is manufacturing pharmaceutical formulations such as Oral Liquids, Dry syrups, Sachets, External Preparations, Beta and Non-Beta Lactam tablets, and Capsules & Nutritional Food supplements.

Vilin Bio Med (NSE:VILINBIO) Headlines

No Headlines